Last updated 2026-07-27
TL;DR
Sirolimus Rx connects patients with provider-reviewed sirolimus (rapamycin), a drug that blocks the mTOR pathway involved in cell growth and aging. It's FDA-approved for organ transplant rejection, not longevity. Mouse studies from the NIA Interventions Testing Program show 9-26% lifespan extension. No completed human lifespan trial exists. Everything about aging use is off-label and unproven in people.
What is sirolimus and how is it related to rapamycin
Sirolimus and rapamycin are the same molecule. Rapamycin was the original name, discovered in a soil sample from Easter Island (Rapa Nui) in the 1970s, isolated from the bacterium Streptomyces hygroscopicus [1]. When it became a pharmaceutical product, it was marketed under the generic name sirolimus. You'll see both names used interchangeably in research papers, and that's not a marketing trick, it's just naming history. The drug works by inhibiting a protein complex called mTOR (mechanistic target of rapamycin). mTOR sits at the center of a cell signaling pathway that controls growth, metabolism, and a cellular cleanup process called autophagy. Block mTOR, and cells shift out of growth mode and into a more conservative, maintenance-focused state. That shift is the entire basis for interest in sirolimus as a longevity compound. The FDA approved sirolimus (brand name Rapamune) in 1999 for prevention of organ transplant rejection [1]. Two other formulations exist for different indications: Fyarro (albumin-bound sirolimus) for a rare soft tissue cancer called malignant perivascular epithelioid cell tumor, and Hyftor, a topical sirolimus gel for facial angiofibromas in tuberous sclerosis complex [2]. None of these approvals cover aging, lifespan extension, or 'longevity.' Any use for that purpose is off-label, full stop.
What does Sirolimus actually provide to a patient
Sirolimus Rx connects longevity-minded patients with licensed prescribers who evaluate whether off-label sirolimus is appropriate, then routes the prescription to a pharmacy partner for fulfillment. The company doesn't manufacture or compound the drug itself. It sits in the provider-review and access layer: intake, medical screening, prescription, and coordination with a pharmacy that dispenses the medication. That structure matters because sirolimus is a real prescription drug with real interaction risks and a narrow safety margin in transplant use. A model that skips physician review is a bad idea. A model that includes it still doesn't make the underlying human longevity evidence any stronger, it just means a licensed clinician is the one deciding whether your labs, medications, and risk profile make off-label use reasonable for you specifically. If you're already decided and want the practical side of things, dosing protocols and injection logistics are covered separately: see Sirolimus Rx dosage and the Sirolimus Rx dosage calculator.
What is the mTOR pathway and why does it matter for aging
mTOR is short for mechanistic target of rapamycin, a kinase that integrates signals about nutrient availability, energy status, and growth factors to decide whether a cell should grow and divide or conserve resources. It exists in two complexes, mTORC1 and mTORC2. Rapamycin's classic action is inhibiting mTORC1; at higher doses or with chronic exposure it can also affect mTORC2, which is part of why dosing strategy matters so much in the safety conversation. The aging-biology argument goes like this: mTORC1 hyperactivity is linked to reduced autophagy (the process that clears damaged proteins and organelles), stem cell exhaustion, and cellular senescence, all processes implicated in aging phenotypes across species. Caloric restriction, one of the most reproducible lifespan-extending interventions in lab animals, appears to work partly by suppressing mTORC1. Rapamycin is interesting precisely because it mimics part of that effect pharmacologically without requiring an animal to actually eat less [3]. This is a mechanistic story, not a guarantee. Plenty of drugs with elegant mechanisms have failed to translate into clinical benefit. The mTOR hypothesis is genuinely one of the best-supported aging pathways in modern biology, but 'well-supported pathway' and 'proven human lifespan drug' are different claims, and conflating them is where a lot of the hype online goes wrong.
What does the mouse lifespan data actually show
| ITP 2009 report | 20 months | 14 ppm (low) then 600 ppm encapsulated | ~9% | ~14% | |
|---|---|---|---|---|---|
| ITP later cohorts | 9 months | Higher encapsulated doses | up to ~23% | up to ~26% | Source: NIA Interventions Testing Program summaries [5] [6] Rapamycin is the only compound tested by the ITP that has extended lifespan in every cohort tested so far, at multiple starting ages, in both sexes. That consistency is genuinely rare and is the single strongest argument longevity researchers make for taking the drug seriously. It is not, however, evidence that the same effect occurs in humans, who live roughly 30 times longer than lab mice and differ enormously in genetics, environment, and cause of death. |
The strongest evidence for sirolimus and lifespan comes from the National Institute on Aging's Interventions Testing Program (ITP), a multi-site, standardized program testing compounds in genetically heterogeneous mice across three labs (Jackson Laboratory, University of Michigan, University of Texas Health Science Center at San Antonio) [4]. Standardization across sites is what makes this data more credible than typical single-lab aging studies. In the first ITP cohort, mice started on encapsulated rapamycin at 600 ppm in food beginning at 20 months of age (roughly equivalent to late middle age in humans) showed median lifespan increases of 9% in males and 14% in females compared to controls [5]. Later cohorts starting rapamycin earlier, at 9 months of age, and at higher doses extended median lifespan by up to 23% in males and 26% in females in some reports [6]. Effects have been replicated across multiple independent ITP testing rounds, which is unusual: most 'longevity supplement' claims rest on a single small study that nobody has repeated. | Study cohort | Age started | Dose | Male lifespan gain | Female lifespan gain |
Is there a completed human lifespan trial for sirolimus
No. There is no completed randomized controlled trial in humans measuring lifespan or all-cause mortality as an endpoint for sirolimus used off-label for aging. This is the single most important fact in the entire sirolimus-longevity conversation, and it needs repeating every time the mouse data comes up. What does exist: a small number of short-duration human trials looking at surrogate markers, not lifespan. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), run out of AKG Rejuvenation and published in 2024, tested low-dose rapamycin (5mg or 10mg weekly, or 6mg biweekly) against placebo in about 115 adults over 48 weeks. It found no significant improvement in the primary endpoint (lean tissue mass) but did report improvement in some quality-of-life measures at the 10mg weekly dose. That's a phase-2-style feasibility and biomarker study, not a mortality trial, and it ran less than a year. There's also observational and small interventional work in specific human populations: studies on periodontal/gum health with topical rapamycin, small trials in older adults looking at immune response to vaccination (a 2014 Novartis-sponsored trial found an mTOR inhibitor improved influenza vaccine response in adults over 65) , and skin studies looking at topical rapamycin's effect on senescent cell markers. None of these measure lifespan. Anyone telling you sirolimus is 'proven' to extend human life is overstating what the literature actually contains.
Why hasn't a human lifespan trial for rapamycin been done
Cost and time, mostly. A trial powered to detect a mortality difference in healthy humans would need thousands of participants followed for years, likely a decade or more given that healthy middle-aged adults don't die at high rates over short windows. That kind of trial can cost hundreds of millions of dollars, and there's no clear commercial sponsor: sirolimus is off-patent (generic since the early 2000s), so no pharmaceutical company has the financial incentive to fund a trial that, if successful, mainly benefits generic manufacturers who didn't pay for it. The FDA also doesn't currently recognize 'aging' itself as an indication a drug can be approved to treat, which is part of why the TAME trial (Targeting Aging with Metformin), a proposed large trial design for a different repurposed drug, has struggled for years to secure full funding despite extensive academic support . The same regulatory and funding gap applies to rapamycin. Some researchers argue biomarker-based or composite-endpoint trials could get around the mortality-endpoint problem, but nothing at that scale has completed for sirolimus yet. This is a structural, not a scientific, dead end. It's not that trials failed and showed no benefit. It's that the trials that would actually answer the question haven't been run at the scale needed.
What are the real risks of off-label sirolimus for longevity
The risk profile people ask about most falls into three buckets: immunosuppression, mouth ulcers, and metabolic effects. All three are documented in the transplant literature, where sirolimus is used at continuous, much higher doses than typical longevity protocols, so the magnitude of risk at low intermittent doses is genuinely less certain and less studied. Immunosuppression is the core, FDA-labeled effect of the drug: it's an immunosuppressant, that's the approved use. At transplant doses this significantly raises infection risk. At the low, intermittent (often once-weekly) doses common in off-label longevity protocols, the immune effect appears smaller and some research even suggests improved vaccine response at certain doses , but there is no large safety dataset specifically for healthy adults using intermittent low-dose sirolimus over years. You are extrapolating from a different population and a different dosing schedule. Mouth ulcers (stomatitis) are one of the most commonly reported side effects in sirolimus clinical trials, showing up in a meaningful minority of transplant patients on the drug and also reported anecdotally at high rates in longevity self-experimenters using pulsed weekly dosing . Metabolic effects include increased triglycerides and LDL cholesterol, and in some patients, new-onset hyperglycemia or worsened insulin resistance, effects documented in the Rapamune prescribing information . These aren't rare curiosities; they're listed adverse effects in the FDA label for the approved indication, and they're exactly why anyone using this drug off-label should have baseline and follow-up bloodwork, more than a prescription and a scale. For anyone moving from theory to a protocol, see Sirolimus Rx how to inject, Sirolimus Rx injection sites, and how to reconstitute Sirolimus Rx for the practical mechanics, and Sirolimus Rx cycle length for how intermittent schedules are typically structured.
How is low-dose intermittent dosing different from the transplant dose
Transplant patients take sirolimus daily, continuously, often alongside other immunosuppressants, at doses calibrated to keep blood trough levels in a specific therapeutic range (commonly cited target ranges in transplant protocols run roughly 5-15 ng/mL depending on the regimen and combination therapy) [1]. That's a fundamentally different exposure pattern than what's discussed in longevity circles. The longevity-community protocols popularized by researchers like Dr. Alan Green and studied in small trials like PEARL use once-weekly or biweekly dosing at 5-10mg, explicitly designed to hit mTORC1 hard for a short window and then let blood levels clear before the next dose, in theory sparing mTORC2 and reducing the metabolic and immune side effects seen with continuous daily transplant dosing. This intermittent-dosing theory is plausible and has some support in animal models, but it has not been validated by any large human trial with hard clinical endpoints. It's a reasonable hypothesis being tested in small studies, not an established fact. Anyone considering this route needs individualized dosing guidance from a prescriber, not a forum thread. Details on typical protocols are covered in Sirolimus Rx dosage.
Does sirolimus work the same way as caloric restriction or metformin
They overlap but aren't identical. Caloric restriction is the oldest and most reproducible lifespan-extending intervention in lab animals, and it works through several pathways including suppression of mTORC1 signaling, among other mechanisms (AMPK activation, changes in insulin/IGF-1 signaling). Rapamycin mimics the mTORC1-suppression piece specifically, which is part of why it's sometimes called a 'caloric restriction mimetic,' though that's a simplification. Metformin, the diabetes drug getting similar longevity attention (it's the subject of the proposed TAME trial ), works mainly through AMPK activation and effects on mitochondrial complex I, a different entry point into overlapping metabolic pathways. Both drugs converge on some of the same downstream biology, but they are not interchangeable and have different side effect profiles: metformin's main complaints are gastrointestinal, sirolimus's are immune and metabolic as described above. Neither has a completed human lifespan trial. Both have decent mechanistic stories and repurposing appeal because they're cheap, generic, and have decades of human safety data in their approved indications, which lowers the bar for off-label experimentation compared to a brand-new unapproved compound.
Who should not consider off-label sirolimus at all
Because it's an immunosuppressant, sirolimus is a poor fit for anyone with an active infection, a history of frequent or serious infections, or a condition that already compromises immune function. It's also flagged in its FDA label with a boxed warning history related to increased risk of infection and lymphoma/skin cancer in transplant patients on combination immunosuppressive regimens [1], and while that boxed risk context is specific to transplant polypharmacy, it's still a serious signal for anyone weighing off-label use. People with poorly controlled diabetes or significant hyperlipidemia should be cautious given the drug's documented effects on glucose and lipids . Pregnant or breastfeeding people should not use it; sirolimus crosses into breast milk and has reproductive toxicity data in animal studies cited in its label [1]. Anyone with planned surgery should flag sirolimus use to their surgical team, since it's associated with wound healing complications in the transplant literature. This is exactly the kind of decision that should go through a licensed prescriber who can review your full medical history and current medications, not a self-directed purchase. That's the entire reason a provider-reviewed model exists in the first place.
What should a longevity researcher actually take away from this
The mechanistic case for mTOR inhibition as an aging-relevant pathway is strong. The animal data, especially from the NIA's Interventions Testing Program, is some of the most replicated lifespan-extension data in mammalian aging research, showing consistent gains across independent cohorts and both sexes [5] [6]. That's genuinely a stronger evidence base than almost any other longevity compound getting attention right now. What's missing is the human half of the story. No completed trial has measured whether sirolimus extends human lifespan or reduces all-cause mortality, and the short human trials that exist (PEARL and similar) look at biomarkers and quality-of-life measures over less than a year, not survival over decades. Anyone using it off-label for longevity is running a personal experiment based on strong preclinical rationale and weak-to-absent direct human outcome data, with known, real side effects (immunosuppression, mouth ulcers, metabolic shifts) that are well documented at transplant doses and less well characterized at low intermittent doses. If you decide the risk-reward makes sense for you, the responsible path is provider-reviewed: real bloodwork, a real prescriber who checks your history and current medications, and a real pharmacy filling the prescription, rather than buying research-chemical-grade powder online. Sirolimus Rx exists specifically to route people through that provider-review step and connect them with a pharmacy partner for fulfillment; it doesn't compound or manufacture the drug itself, and it can't make the human evidence any more complete than it currently is.
Frequently asked questions
Is sirolimus the same as rapamycin?
Yes. Rapamycin is the original chemical name for the compound discovered on Easter Island in the 1970s. Sirolimus is the generic pharmaceutical name used once it became an FDA-approved drug in 1999. You'll see both terms in research papers and products; they refer to the identical molecule.
Has rapamycin been proven to extend human lifespan?
No. There is no completed human trial measuring lifespan or mortality for rapamycin. The strongest lifespan data is in mice from the NIA's Interventions Testing Program, showing 9-26% median lifespan increases. Short human trials like PEARL (2024) measured biomarkers over 48 weeks, not survival.
What is Sirolimus and does it manufacture the drug?
Sirolimus Rx connects patients with a provider-review process for off-label sirolimus and coordinates with a pharmacy partner that fulfills the prescription. It does not compound or manufacture sirolimus itself; a licensed pharmacy handles fulfillment after a prescriber reviews the patient's medical history.
What is mTOR and why does rapamycin target it?
mTOR (mechanistic target of rapamycin) is a protein complex that regulates cell growth, metabolism, and autophagy based on nutrient and energy signals. Rapamycin inhibits mTORC1, shifting cells toward a maintenance state similar to what caloric restriction produces, which is why it's studied as an aging-relevant intervention.
How much does rapamycin extend lifespan in mice?
In NIA Interventions Testing Program cohorts, median lifespan increased about 9% in males and 14% in females when started at 20 months of age, and up to roughly 23% in males and 26% in females in later cohorts starting treatment at 9 months with higher doses.
What is the PEARL trial and what did it find?
PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) was a 2024 trial of about 115 adults testing weekly low-dose rapamycin over 48 weeks. It found no significant change in its primary endpoint, lean tissue mass, but reported some quality-of-life improvements at the 10mg weekly dose.
Is sirolimus FDA-approved for anti-aging use?
No. Sirolimus is FDA-approved to prevent organ transplant rejection (as Rapamune), and separately as Fyarro for a rare cancer and Hyftor for tuberous sclerosis-related skin lesions. Any use for aging or longevity is off-label and not an FDA-recognized indication.
What are the main side effects of off-label sirolimus use?
The most commonly reported issues are immunosuppression (increased infection risk), mouth ulcers (stomatitis), and metabolic effects including elevated triglycerides, LDL cholesterol, and blood sugar. These are documented in transplant-dose studies; risk at low intermittent longevity doses is less well studied.
Why hasn't anyone run a human lifespan trial for rapamycin?
Cost and structure. A trial detecting mortality differences in healthy adults would need thousands of participants followed for a decade or more, likely costing hundreds of millions of dollars. Since sirolimus is generic, no drug company has a commercial incentive to fund it, and the FDA doesn't currently approve drugs for 'aging' as an indication.
Is low-dose weekly dosing safer than daily transplant dosing?
It's theorized to be, based on the idea that intermittent high peaks preferentially inhibit mTORC1 while sparing mTORC2, reducing metabolic side effects. This idea has support in animal studies and small human trials, but hasn't been validated in a large human trial with hard clinical endpoints.
Does rapamycin work like metformin or caloric restriction?
It overlaps but isn't identical. Caloric restriction and rapamycin both suppress mTORC1 signaling among other mechanisms. Metformin mainly works through AMPK activation and mitochondrial effects. All three converge on some shared aging-relevant pathways, but none have completed human lifespan trials.
Who shouldn't use sirolimus off-label?
People with active infections, a history of frequent infections, poorly controlled diabetes, significant hyperlipidemia, or anyone pregnant or breastfeeding should avoid it. Anyone with planned surgery should disclose use to their surgical team given documented wound-healing risks in the transplant literature.
Where does the strongest sirolimus longevity evidence come from?
The NIA Interventions Testing Program, a standardized multi-site mouse study across Jackson Laboratory, University of Michigan, and UT Health San Antonio. Rapamycin is the only compound the program has tested that extended lifespan in every cohort tried so far, across multiple starting ages and both sexes.
Sources
- NIH National Institute on Aging, rapamycin discovery history: Rapamycin was discovered in a soil sample from Easter Island (Rapa Nui) from the bacterium Streptomyces hygroscopicus
- National Institute on Aging, Interventions Testing Program: The ITP is a standardized, multi-site NIA program (Jackson Lab, University of Michigan, UT Health San Antonio) testing compounds for lifespan effects in genetically heterogeneous mice
- Harrison DE et al., Nature 460:392-395 (2009), PMID 19587680: Rapamycin started at 20 months of age extended median lifespan approximately 9% in males and 14% in females in the first ITP cohort
- Miller RA et al., Journals of Gerontology Series A (2011), PMID 21367943: Later ITP cohorts starting rapamycin at 9 months and using higher encapsulated doses extended median lifespan up to approximately 23% in males and 26% in females
- PEARL trial, Aging (Albany NY) 2024, PMID 38295054: The PEARL trial tested weekly and biweekly low-dose rapamycin against placebo in about 115 adults over 48 weeks; primary endpoint of lean tissue mass showed no significant difference
- Mannick JB et al., Science Translational Medicine 6(268):268ra179 (2014): An mTOR inhibitor improved influenza vaccine antibody response in adults over 65 in a Novartis-sponsored randomized trial